ClinicalTrials.gg
Active, not recruitingNCT03474770FIASUpdated Aug 30, 2022

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

A Phase 1/2 interventional study of BIS-001ER in Focal Impaired Awareness Seizures, sponsored by Supernus Pharmaceuticals, Inc.. Active, not recruiting at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-30.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 56 studies in Seizures with a site in Australia — 14 open to participants now, 20 under way, 12 of them phase 3. Seizures · Australia.

Planned enrollment
48th of 53
16 · median 216
Started
2018
with 6 others
Phase 1/2
Only one
of the 56
Primary completion
2026-12
later than 4 of 19 live
Registered
23rd of 56
by date
Lead sponsor
4 of 56
Supernus Pharmaceuticals, Inc.

Among the 56 studies in Seizures with a site in Australia, this one is the 48th largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2018, is the only one in phase 1/2, reaches primary completion later than 4 of the 19 other live ones, and was the 23rd registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

14 of the 56 studies in Seizures with a site in Australia are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Seizures with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

03

Conditions studied

  • Focal Impaired Awareness Seizures

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Speak English with sufficient proficiency to read and comprehend the document, and to communicate with study staff.
  • Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
  • Have signed the Informed Consent before any study-specific procedures are performed.
  • Be males or females between 18 - 65 years of age.
  • Have a diagnosis of FIAS type epilepsy with or without additional focal aware or non-aware seizures with generalization.
  • Have a current minimum average of 5 countable seizures / week to enroll in study.
  • Have at least 5 focal impaired awareness seizures during the 96-hour baseline VEM period.
  • Be receiving stable doses (for at least 4 weeks) of one to four currently marketed anti-epileptic drugs (AEDs), with or without vagus nerve stimulation (in which case the patient should be on the same stimulation parameters for at least 4 weeks).
  • Have a negative urinary pregnancy test upon admission to the site on Day 1.
  • Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead , and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
  • Be able to comply with all study-specified procedures.
  • Weight between 40 and 120 kg.

Exclusion criteria

Exclusion Criteria:

  • Has taken Huperzine A within the past year.
  • Is planning to become pregnant or impregnate spouse, not using an acceptable method of (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing.
  • Have non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
  • Has seizures that are difficult to count; for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
  • Have less than the 5 minimum accepted seizures required during baseline evaluation period screen.
  • Have a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
  • Has attempted suicide within the past 2 years.
  • Has a history of status epilepticus in the 6 months previous to enrollment.
  • Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the Principal Investigator's opinion, could interfere with the participant's suitability for participation in the study.
  • Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
  • Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator.
  • Is on concomitant therapy with non-AEDs that are cholinergic.
  • Has participated in any clinical drug or device study within four weeks prior to study entry.
  • Inability to complete seizure diary.
  • Is currently taking or has taken Epigallocatechin gallate (EGCG) within the past 14 days, or consume foods or drinks containing EGCG; including green, white, oolong teas and certain black teas, or food containing >100grams of carob powder within the past 14 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    BIS-001ER

    Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.

    Drug: BIS-001ER

Interventions

  • DrugBIS-001ER

    BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.

    Also known as: Huperzine A ER

06

What researchers measure

Primary outcomes

  1. Effect of BIS-001ER on Seizure Count

    Reduction in average daily seizure count between baseline (pre-treatment) and evaluation (on treatment) video EEG monitoring periods.

    Time frame: 6 Weeks

Secondary outcomes

  1. Effect of BIS-001ER on Percent Reduction in Daily Seizure Count

    Percent reduction in average daily seizure count from the baseline VEM period compared to the evaluation video EEG monitoring period (on treatment).

    Time frame: 6 Weeks

  2. Effect of BIS-001ER on Seizure Count vs Titration Period (Diary)

    Percent reduction in average number of seizures from the baseline period. (screening/retrospective diary) compared to the last week of the titration treatment period.

    Time frame: 6 Weeks

  3. Percent of Treatment Responders

    Percent of participants considered treatment responders defined as those with a ≥25%, ≥50%, ≥75% reduction in seizures from the baseline VEM period compared to the VEM treatment evaluation period.

    Time frame: 6 Weeks

  4. Effect of BIS-001ER on Seizure Count During Extension Phase

    Percent reduction of average number of seizures vs. baseline/retrospective diary at 1, 3, 6, 12 months during the extension period.

    Time frame: 12 Months

  5. Complete Seizure Protection

    Proportion of subjects with 100% seizure reduction.

    Time frame: 6 Weeks

  6. Need for Rescue Medication

    Proportion of subjects requiring rescue medication at different dosages.

    Time frame: 6 Weeks

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Mar 23, 2018
StartActual
Apr 10, 2018
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03474770
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
Apr 10, 2018
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 30, 2022

Study contacts

Azmi Nasser, PhD
study chair · Supernus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion